Form 8-K · Current report
AbbVie 8-K, filed Oct 5, 2026
- Filed
- CIK
- 0001551152
- Accession no.
- 0001551152-26-000030
Summary
AbbVie said its third-quarter 2026 earnings will include $216 million of pre-tax acquired IPR&D and milestones expense, an unfavorable $0.11 impact on both GAAP and adjusted non-GAAP diluted earnings per share, and revised its 2026 adjusted diluted EPS guidance to $13.76-$13.96 and its third-quarter guidance to $3.73-$3.77. AbbVie said the quarter's results are not final and may differ from the preliminary estimates.
Key points
- AbbVie said third-quarter 2026 GAAP and adjusted non-GAAP diluted earnings per share will each take an unfavorable $0.11 hit from $216 million of pre-tax acquired IPR&D and milestones expense.
- Full-year 2026 adjusted diluted earnings per share guidance, including that expense, is $13.76 to $13.96, down from the previously announced $13.87 to $14.07 range.
- Third-quarter 2026 adjusted diluted earnings per share guidance, including the expense, is $3.73 to $3.77, against $3.84 to $3.88 excluding it.
- Results for the quarter ended September 30, 2026 have not been finalized and the July 31, 2026 guidance excluded IPR&D and milestones expense incurred beyond the second quarter of 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2026 are expected to include acquired IPR&D and milestones expense of $216 million on a pre-tax basis, representing an unfavorable impact of $0.11 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended September 30, 2026 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.